Nilotinib 300 Mg Twice Daily Is Effective and Well Tolerated as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Preliminary Results of the ICORG 0802 Phase 2 Study

M.C. O'Dwyer, E. Kent, M. Parker, R.T. Swords, F. Giles, P. Le Coutre, S. Padmanabhan, B. Moulton, Mary Frances McMullin, S. Langabeer, K. Egan, E. Conneally

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)1277-1277
Number of pages1
Publication statusPublished - Dec 2009

Cite this